 Home > Biochemical Engineering > Polypeptide > Orforglipron for Sale > Orforglipron 2212020-52-37 API is a non-peptide glucagon-like peptide-1 (GLP-1)

Orforglipron 2212020-52-37 API is a non-peptide glucagon-like peptide-1 (GLP-1)

Name: Orforglipron 2212020-52-37 API is a non-peptide glucagon-like peptide-1 (GLP-1)
Brand: focuses
SKU: pr2508291523
Price: 1 USD
Availability: InStock

27 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2212020-52-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

ningbo

Brand:

focuses

Packaging:

as requires

Price valid (until):

2025-09-29

Contact Supplier

 Chat Now

Fujian Genohope Biotech Ltd.

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

 Visit Store

Product Description
Seller Information
Inquiry History

Description
Product Detail

Orforglipron is a novel oral non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist primarily indicated for the treatment of type 2 diabetes mellitus (T2DM) and obesity. By activating GLP-1 receptors, it promotes glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels and reducing body weight.
As the first oral small-molecule GLP-1 drug to complete Phase III clinical trials, Orforglipron offers superior patient adherence (once-daily oral administration without dietary restrictions) compared to injectable formulations, potentially reshaping the landscape of GLP-1-based therapies.

Product Key Quality Analysis: The structure of the product was confirmed by Mass, IR, 1H NMR and 13C NMR. The purity and content were detected by HPLC. The purity of the product was more than 99.0%, total impurities was less than 1.0% and single impurity was less than 0.2%.

Chemical Name：3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one

Molecular weight：882.97

Molecular formula：C ₄₈H ₄₈F ₂N ₁₀O ₅

CAS Number：2212020-52-3

Storage conditions ：Sealed,protected from light, -20℃±5℃

Manufacturing Process: Chemical synthesis

PRODUCT ADVANTAGES
GMP System is complied with both China NMPA and US FDA.
Stable quality: During mass production, with batch size over kg grade, the quality can be assured to be stable in successive productions, and the quality between batches has minor difference, which shows stable quality.
Fully synthesized, high purity.low impurities
Price: Most competitive pricing in the market
Support: The experienced team provides supports of full-life stages, including R&D, manufacturing, registration and commercialization in the peptide industries.

Our Factory

Fujian Genohope Biotech Ltd was established in 2019, It was co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation. The company is located in the national "Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone" in Putian City, Fujian Province. The company has 260 employees, and in 2023, the company was selected as a Specialized in special innovative enterprises in Fujian Province.

The company focuses on High potency polypeptide API/solution, and sells polypeptide API/solution and preparation production services to the global market. The company covers a total area of 55 mu, with a total construction area of about 70,000 square meters, and has built about 800 square meters of R & D center, 1,000 square meters of quality control center and 3,300 square meters of GMP production workshop. At present, 13 production lines have been built, including 7 production lines for the preparation of recombinant peptide API and fully synthetic peptide API and 6 lines for injections. In addition, the company also has a large anti-tumor injection workshop, a small multi-purpose injection workshop, a large multi-purpose injection workshop. The construction and operation management of the production line meet the regulatory requirements of the global drug market and meet the double registration and declaration of China and the United States. Also can meet the customer registration and sales at home and abroad.

Product superiority：

At present, the company's main products are Semaglutide, Tirzepatide, Retatrutide, cosmetic medicine microspheres, collagen. In particular, the company has the advantage of mature 2 processes preparation of Semaglutide API, Semaglutide API registered in the US FDA (DMF No. : 040957),Tirzepatide API registered in the US FDA (DMF No. : 040503),

Semaglutide API has the following three characteristics: low price, high quality, and large production capacity (tonnage). Tirzepatide API is well received favourable reviews in the pharmaceutical industry of polypeptide .

Our Certificate

FAQ

Q: What does semaglutide do to your body?

A: Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy.

Q: What is the dark side of semaglutide?

A: Pancreatitis (swelling of the pancreas) may occur while you are using this medicine. Check with your doctor right away if you have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.

Q: Who cannot take semaglutide?

A: Thyroid cancer or if someone in your family had thyroid cancer. An unusual or allergic reaction to semaglutide, other medications, foods, dyes, or preservatives. Pregnant or trying to get pregnant. Breast-feeding.

Q: Why do I feel so bad on semaglutide?

A: However, semaglutide also affects the gastrointestinal tract by increasing the amount of glucagon. This has two effects on the digestive tract. First, it slows down the movement of food through your gut, which can lead to nausea, vomiting, and diarrhea.

Q: Can semaglutide be harmful?

A: Nausea, vomiting, and diarrhea are the most common semaglutide side effects. But they usually subside after a few weeks of using the medication. Although rare, serious side effects are possible. Some may require immediate medical attention, such as pancreatitis and allergic reactions.

Q: Can semaglutide damage your pancreas?

A: Does Semaglutide Damage Your Pancreas? Semaglutide has been associated with pancreatitis, which is an inflammation of the pancreas. While pancreatitis can cause damage to the pancreas, the occurrence of this side effect due to semaglutide is considered uncommon.

Q: Can I lose 50 lbs on semaglutide?

A: According to clinical trials, people on a weekly semaglutide dosage can expect to lose an average of 5–10% of their body weight. Patients who were overweight lost 5.9% of their body weight after three months of weekly semaglutide injections. The average weight loss was 10.9% after 6 months of weekly injections.

Q: Is metformin as good as semaglutide?

A: Between these two medications, semaglutide produces more significant weight loss than metformin, but metformin tends to be a more affordable option. But patients can also opt to combine these drugs to maximize their effects with a proper treatment plan.

ECHEMI Editorial Reference

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.
Research & Reference Note

Orforglipron 2212020-52-37 API is a non-peptide glucagon-like peptide-1 (GLP-1) is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sources

PubChem

ClinicalTrials.gov

FDA Drugs@FDA

NIH
Disclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
Basic Info

Product Name:
Orforglipron

Other Name:
1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833

CAS No.:
2212020-52-3

Molecular Formula:
C48H48F2N10O5

InChIKeys:
USUWIEBBBWHKNI-BBGRWQLENA-N

Molecular Weight:
882.97

EC Number:
278-636-5

Color/Form:
Off-white to light yellow

Categories:
Polypeptide

Characteristics

Density:
1.50±0.1 g/cm3(Predicted)

PKA:
7.33±0.20(Predicted)

Critical Temperature & Pressure:
Store at -20°C

See More Orforglipron Properties 
Seller Information

Business Type:
Manufactory

Main Products:
Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

Location:
NO.288,Renyang, Binglun Village, Hushi Town, Xiuyu DistrictPutian City, Fujian Province 351146, China (CHN)

Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
2

Total Annual Revenue:
$25 million-$50 million

Total Employees:
201-300

Year of Establishment:
2019

Certifications:
DMF ACKNOWLEDGEMENT,Notice of GMP Compliance Inspection

Company Profile

Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province.

The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.

In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.

Inquiry History

27 Inquiries

Country	Product	Purchase Quantity	Date Posted
Bulgaria	orforglipron	1 KG	Aug 27, 2025
Austria	Orforglipron	1000 MT	Jun 12, 2026
Switzerland	Orforglipron	10 MG	Apr 25, 2026
United States	Orforglipron	20 G	Apr 3, 2026
United States	Orforglipron	10 G	Mar 29, 2026
United States	oforglipron	3 KG	Jul 4, 2025
United Kingdom	Orforglipron	1 G	Jul 9, 2026
Belgium	Orforglipron	1 G	Jun 14, 2026
Puerto Rico	Orforglipron	1 G	Mar 2, 2026
United States	Orforglipron	10 G	Oct 24, 2025
United States	Orforglipron	1 G	Sep 30, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	orforglipron	1 MT	Sep 20, 2025
United States	Orforglipron	1 KG	Apr 18, 2025
Canada	LY-3502970	10 G	Feb 26, 2026
India	orforglipron	1.00 G	Jul 16, 2026
United States	orforglipron	10 G	Apr 20, 2026
United States	Orforglipron	10 G	Apr 6, 2026
United States	orforglipron	1 G	Mar 24, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
2212020-52-3 Orforglipron-LY3502970	/99	$5-6/KG FOB	Conier Chem&Pharma Limited	Inquiry
Orforglipronn	/		Shandong zhishang chemical Co.,Ltd	Inquiry
Weight Loss 99% Orforglipron/LY3502970/LY-3502970 CAS: 2212020-52-3 Best Quality	Pharmaceutical Grade/99.9	$90-115/G FOB	Hangzhou Hyper Chemicals Limited	Inquiry
Orforglipron LY3502970 receptor agonist 1 2212020-52-3	Pharmacy Grade/99	$90-110/G FOB	Dingwang Technology (Wuhan) Co., Ltd.	Inquiry
Orforglipron CAS: 2212020-52-3	/		SHANDONG LOOK CHEMICAL CO.,LTD	Inquiry

Orforglipron 2212020-52-37 API is a non-peptide glucagon-like peptide-1 (GLP-1)

Product Description

Seller Information

Inquiry History

Our Factory

Our Certificate

More Choices Find All Products for Sale 

Related Searches